Akston Biosciences
  • Programs
    • Pipeline
    • Platform
    • Process
  • Company
    • Overview
    • Leadership
    • Facilities
    • Partners
    • Contact
  • Careers
    • Overview
    • Career Opportunities
    • Our Culture
    • Contact
  • News
    • Overview
    • In The News
    • Press Releases
    • Papers

Papers

23 February 2023

A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452

27 May 2022

Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs

23 February 2022

Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

15 February 2022

Abstract P4-02-01: Targeting insulin receptor in estrogen receptor positive breast cancer

16 October 2021

Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452

16 June 2021

An ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in cats

16 January 2021

Disrupting Insulin and IGF Receptor Function in Cancer

15 February 2020

Abstract P1-21-05: A novel long-acting insulin for cancer therapy reduces xenograft tumor growth

Akston BioSciences

info@akstonbio.com |

  • Home
  • Company
  • Pipeline
  • Careers
  • Press Releases
  • Contact

©2023 Akston Biosciences Corporation